177lu-rhpsma-10.1
PeptideexperimentalImaging agent
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 20, 2022 (NCT05413850)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 177-lutetium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06516510 | Early Phase 1 (Phase 1) | Oct 31, 2024 | Bracco, Medpace, Inc. |
| NCT06066437 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2023 | Bracco, University of Texas at Houston |
| NCT06105918 | Phase 1 | Nov 29, 2023 | Emory University, National Cancer Institute (NCI) |
| NCT05413850 | Phase 1/Phase 2 (Phase 2) | Jul 20, 2022 | Bracco, PSI CRO |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bracco | For profit | 3 | 2 | 2 | 2022 |
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Medpace, Inc. | For profit | 1 | 0 | 1 | 2024 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2023 |
| PSI CRO | For profit | 1 | 0 | 1 | 2022 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2023 |
6 organizations
Page 1 / 1